- Conditions
- Breast Cancer
- Interventions
- trastuzumab, paclitaxel
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 603
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- Romidepsin, Abraxane
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- flow cytometry, fluorescence activated cell sorting, immunohistochemistry staining method, immunologic technique, biomarker analysis
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Breast Cancer
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride, imatinib mesylate
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Camden, New Jersey + 5 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Copanlisib, Pertuzumab, Trastuzumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 27 more
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- trastuzumab, alvocidib, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- physiologic testing
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Breast Cancer, Metastatic Cancer
- Interventions
- dasatinib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 117
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 76 more
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
- Interventions
- G1T48, Palbociclib
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
- Interventions
- Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Newport Beach, California • Boston, Massachusetts + 2 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 652
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
- Conditions
- Breast Cancer, Metastatic Cancer
- Interventions
- lapatinib ditosylate, gene expression analysis, diagnostic laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, erlotinib hydrochloride
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, paclitaxel, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, paclitaxel
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- CP-724,714
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- cisplatin, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
- Conditions
- Breast Cancer
- Interventions
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
- Interventions
- Zoledronic acid, Standard Therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 30 more
- Conditions
- Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
- Interventions
- hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
- Radiation · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois